Cohesin mutations in myeloid malignancies made simple
Purpose of review Recurrent loss of function mutations within genes of the cohesin complex have been identified in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). STAG2 is the most commonly mutated cohesin member in AML as well as solid tumors. STAG2 is recurrently, mutated in Ewing's Sarcoma, bladder cancer, and glioblastoma, and is one of only ten genes known to be recurrently mutated in over four distinct tissue types of human cancer Recent findings The cohesin complex, a multiprotein ring, is canonically known to align and stabilize replicated chromosomes prior to cell division. Although initially thought to lead to unequal chromosomal separation in dividing cells, data in myeloid malignancies show this is not observed in cohesin mutant MDS/AML, either in large patient cohorts or mouse models. Mounting evidence supports a potential alternate mechanism whereby drivers of cell-type specific gene expression and hematopoietic development are impaired through alteration in three-dimensional nuclear organization and gene structure. Summary Understanding the functional consequences of cohesin mutations in regulating lineage-specific and signal-dependent defects and in myeloid transformation will identify novel pathophysiologic mechanisms of disease and inform the development of novel therapeutic targets.
CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States. PMID: 29469047 [PubMed - in process]
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
February 23, 2018—(BRONX, NY)—Earlier this week, in a crowded conference room in the Price Center/Block Pavilion, members of the Einstein-Montefiore community hosted a special visit from U.S. Congressman Joseph Crowley (D-NY, 14th District). At his office’s request, Rep. Crowley met with more than a dozen BOLD Buddies, volunteer peer mentors who provide support for cancer patients and survivors in the Bronx. Members of the group shared their personal stories and explained commitment to offer their support, hope and encouragement to others facing cancer and treatment at all stages of disease.
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a doctor.
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Norton Healthcare is customizing treatment rooms for the best patient and provider experience.
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
e;ndez I, Rodríguez-Acosta A Abstract Crotamine is a cationic, non-enzymatic, protein integrating a minor family of myotoxins, composed of 42 amino acid residues, described in Viperidae and Crotalidae snake's families that has been used in neuroscience research, drug progressing and molecular diversity reports. Crotamine-like protein (CLP) from C.o.helleri venom was isolated in fraction 5 from 7 peaks obtained by sulfopropyl waters protein pak cationic exchange column. In tricine-SDS-PAGE under non-reduced conditions this CLP showed a single band of ~8 kDa molecular weight. CLP induced toxicity of K-56...
The European committee recommended against approval of neratinib (Nerlynx) for breast cancer, even though the drug has been approved in the United States.International Approvals